Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RGLS

Regulus Therapeutics Inc

Dec 12 • 04:00PM ET

1.60

Dollar change -0.10
Percentage change -5.88	%

Healthcare • Biotechnology • USA • NASD

Peers: IONS ARWR SRPT MRNA RNA ALNY SGMO PRQR WVE BBIO

| Held by: VTI IWM VXF IWN VTWO IWC RSSL VTWV VTWG UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	19.20%	Shs Outstand	65.50M	Perf Week	5.96%
Market Cap	104.80M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	0.03%	Shs Float	52.93M	Perf Month	2.56%
Income	-41.63M	PEG	-	EPS next Q	-0.21	Inst Own	69.93%	Short Float	2.65%	Perf Quarter	-0.62%
Sales	0.00M	P/S	-	EPS this Y	46.10%	Inst Trans	-9.20%	Short Ratio	3.91	Perf Half Y	-35.48%
Book/sh	1.33	P/B	1.21	EPS next Y	-45.40%	ROA	-63.31%	Short Interest	1.40M	Perf Year	18.52%
Cash/sh	1.33	P/C	1.20	EPS next 5Y	39.60%	ROE	-72.36%	52W Range	1.08 - 3.79	Perf YTD	25.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.96%	ROI	-47.69%	52W High	-57.78%	Beta	1.60
Dividend TTM	-	Quick Ratio	13.65	Sales past 5Y	1867.07%	Gross Margin	-	52W Low	48.15%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	13.65	EPS Y/Y TTM	32.26%	Oper. Margin	-	RSI (14)	53.19	Volatility	7.34% 6.65%
Employees	30	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	10.33
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	46.11%	Payout	-	Rel Volume	0.72	Prev Close	1.70
Sales Surprise	-	EPS Surprise	-24.04%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	358.33K	Price	1.60
SMA20	3.80%	SMA50	4.88%	SMA200	-15.05%	Trades		Volume	258,660	Change	-5.88%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-24	Initiated	Oppenheimer	Outperform	$7
Mar-18-24	Initiated	Leerink Partners	Outperform	$6
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral	$1
Jan-05-18	Initiated	Leerink Partners	Outperform	$2
Jun-13-17	Reiterated	Chardan Capital Markets	Buy	$5 → $2.50
Mar-06-17	Reiterated	Wedbush	Outperform	$8 → $6
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-30-17	Downgrade	Needham	Buy → Hold
Dec-07-16	Reiterated	Chardan Capital Markets	Buy	$12 → $5
Nov-02-16	Reiterated	Needham	Buy	$10 → $9
Jul-25-16	Reiterated	Chardan Capital Markets	Buy	$14.50 → $12
Jun-28-16	Reiterated	Needham	Buy	$25 → $10
Jun-28-16	Reiterated	FBR Capital	Outperform	$30 → $9
Jun-28-16	Reiterated	Chardan Capital Markets	Buy	$20 → $13.50
Jun-07-16	Reiterated	Chardan Capital Markets	Buy	$15 → $20
Apr-13-16	Initiated	Chardan Capital Markets	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform	$30
Nov-24-14	Initiated	Deutsche Bank	Buy	$30

Show Previous Ratings

Nov-26-24 08:00AM	Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences (PR Newswire)
Nov-07-24 05:13PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates (PR Newswire)
Oct-29-24 06:01AM	These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts (TipRanks) +7.33%
Oct-08-24 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -9.36%
08:00AM	Loading…
Aug-28-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) -7.78%
Aug-08-24 05:19PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates (PR Newswire)
Aug-06-24 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-09-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire)
Jun-24-24 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -18.33%
Jun-04-24 08:00AM	Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes (PR Newswire)
May-16-24 08:00AM	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer (PR Newswire)
May-09-24 10:57PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
05:16PM	Regulus: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates (PR Newswire)
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace) -8.23%
May-06-24 08:00AM	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.30%
Apr-30-24 08:00AM	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series (PR Newswire) -8.73%
Mar-23-24 05:33AM	Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements (GuruFocus.com)
Mar-21-24 10:53PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.20%
04:22PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates (PR Newswire)
Mar-13-24 12:09PM	Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study (Zacks)
Mar-12-24 06:32AM	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity (PR Newswire) +71.01%
06:30AM	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jan-02-24 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Nov-22-23 08:00AM	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -5.11%
Nov-09-23 04:32PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance) -5.21%
04:05PM	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates (PR Newswire)
08:00AM	Loading…
Nov-02-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +9.76%
Oct-19-23 08:00AM	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-20-23 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -20.61%
Sep-13-23 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +13.70%
Sep-05-23 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) +10.60%
Aug-24-23 07:33PM	Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap? (GuruFocus.com) +17.33% -6.25%
Aug-23-23 01:04PM	Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) +17.19%
08:00AM	Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 (PR Newswire)
Aug-08-23 04:43PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Aug-02-23 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-18-23 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference (PR Newswire)
Jun-27-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +6.72%
Jun-23-23 08:00AM	Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors (PR Newswire)
Jun-20-23 08:00AM	Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital (PR Newswire) -8.67%
Jun-12-23 08:00AM	Regulus Therapeutics Strengthens Research & Development Leadership (PR Newswire) +8.15%
May-16-23 08:00AM	Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.45%
May-11-23 04:18PM	Regulus: Q1 Earnings Snapshot (AP Finance) +15.33%
04:05PM	Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Apr-13-23 08:00AM	Regulus Therapeutics Announces $15 Million Private Placement of Equity (PR Newswire) +35.54%
Apr-12-23 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.24%
Mar-23-23 04:52PM	Regulus: Q4 Earnings Snapshot (AP Finance) -8.49%
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates (PR Newswire)
Feb-09-23 08:00AM	Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Jan-13-23 04:05PM	Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Jan-09-23 06:01AM	Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics (Benzinga)
Dec-12-22 08:00AM	Regulus Therapeutics Announces Resignation of Board Member (PR Newswire) +8.70%
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
08:00AM	Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations (PR Newswire)
Nov-10-22 04:05PM	Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Nov-03-22 08:00AM	Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -5.52%
Nov-02-22 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.07%
Sep-13-22 11:58AM	Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study (Zacks) +10.31%
Sep-12-22 11:14AM	Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease (Benzinga) +15.48%
08:00AM	Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-02-22 04:05PM	Regulus Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +5.19% +14.08%
Aug-11-22 04:10PM	Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Aug-04-22 08:00AM	Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) +14.09%
Jun-21-22 08:00AM	Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-13-22 08:00AM	Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-02-22 08:00AM	Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK (PR Newswire)
May-17-22 04:30PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.56%
07:00AM	7 Penny Stocks With 10x Potential This Year (InvestorPlace)
May-12-22 04:05PM	Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates (PR Newswire) -7.67% -12.34%
10:20AM	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug (Zacks)
May-11-22 08:00AM	Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +54.83%
May-05-22 04:05PM	Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -6.41%
Mar-24-22 12:03PM	Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital (Benzinga)
08:00AM	Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital (PR Newswire)
Mar-10-22 04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates (PR Newswire) -5.63%
Mar-03-22 05:15PM	Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call (PR Newswire) -5.28%
Feb-24-22 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome (PR Newswire)
Feb-10-22 04:30PM	Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (PR Newswire)
Jan-26-22 10:00AM	Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jan-20-22 05:18PM	Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429 (PR Newswire) -8.53%
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... (GuruFocus.com) -7.83%
Jan-04-22 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference (PR Newswire)
Dec-03-21 08:30AM	Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development (PR Newswire) -6.85%
Dec-01-21 08:30AM	Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit (PR Newswire) -6.55%
Nov-30-21 05:23PM	Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity (PR Newswire)
Nov-24-21 04:05PM	Regulus Therapeutics Announces Private Placement of Equity (PR Newswire) +8.68%
Nov-10-21 05:45PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.58%
04:05PM	Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates (PR Newswire)
Nov-03-21 05:15PM	Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call (PR Newswire)
Oct-28-21 03:05PM	Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-13-21 03:11PM	Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher (Benzinga) -29.88%
12:27PM	Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge (Benzinga)
07:27AM	20 Stocks Moving in Wednesday's Pre-Market Session (Benzinga)
Oct-12-21 04:05PM	Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease (PR Newswire)
Sep-30-21 04:45PM	Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science (PR Newswire)

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Collier Kathryn J	Director	Jul 25 '24	Buy	1.82	4,000	7,280	6,740	Jul 29 04:18 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 18 '24	Sale	1.19	5,468	6,510	5,782	Jan 18 08:24 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 18 '24	Sale	1.19	5,468	6,510	10,056	Jan 18 08:23 PM
Hagan Joseph P	Chief Executive Officer	Jan 18 '24	Sale	1.19	14,580	17,359	57,112	Jan 18 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGLS

Regulus Therapeutics Inc

Upgrade your FINVIZ experience